SCT NEWS

Single Cell Technology, Inc. (SCT) today announced the completion of their antibody discovery intellectual property portfolio with the granting of their third United States patent, US Patent No. 9328172, “Method of obtaining antibodies of interest and nucleotides encoding same”. Their portfolio of three foundational patents cover the screening of immune cells on massively parallel arrays and identifying natively paired light and heavy chain sequences with high accuracy.

An additional patent application is pending covering universal addressing on the massive array so that each microwell can be uniquely identified in an auxiliary microscope or computer vision image. This innovation together with the error correction tags developed to pair native light and heavy antibody chains represent significant innovation in the field of antibody discovery.

Dr. Chun-Nan Chen, Founder and CEO of SCT remarked: “Our recently granted third US patent, together with the earlier issued two patents, form a strong portfolio that enables rapid discovery of high affinity antibodies. The field of antibody discovery has not seen such fundamental innovations since Cesar Milstein invented hybridomas in 1975. In a very similar way, our inventions will be used by researchers and businesses to find life saving antibodies for the next 40 years.”

Single Cell Technology, Inc. (SCT) has pioneered a new approach to antibody discovery. Antibodies from secreting cells are rapidly screened against multiple molecules to measure their affinity and specificity and correctly paired mRNA from the cognate light and heavy chains are sequenced by Next Generation Sequencing (NGS). In addition to human and mouse cells, SCT’s technology can be applied to any host that concentrates plasma cells in lymphoid tissues. SCT integrates advances in multiple disciplines, such as wafer fabrication, molecular biology, precision mechanical engineering, nanotechnology, image processing, NGS, and bioinformatics. SCT’s approach substantially decreases the time and investment needed to discover high quality therapeutic and diagnostic antibodies.

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The inclusion of forward-looking statements should not be regarded as a representation that either of the companies’ plans or objectives will be achieved. Forward-looking statements involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statement. These factors include, but are not limited to, uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and the evolution of the market for innovative antibody discovery. The companies undertake no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.